Improving liver health in people with fatty liver disease using insulin treatments
Targeting hepatic mitochondrial function in humans with NAFLD using insulin sensitizers
This study is looking at how certain medications can help improve liver health for people with nonalcoholic fatty liver disease (NAFLD) by making the liver work better and possibly reversing damage caused by too much fat.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11083762 on NIH RePORTER |
What this research studies
This research focuses on understanding and improving liver function in individuals with nonalcoholic fatty liver disease (NAFLD), which can lead to serious liver damage. The study aims to explore how insulin sensitizers can enhance mitochondrial function in the liver, potentially reversing the harmful effects of excess fat. By examining the metabolic processes involved in NAFLD, researchers hope to develop new treatment strategies that target the underlying causes of this condition. Participants may undergo various assessments to evaluate liver health and metabolic responses to the treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with nonalcoholic fatty liver disease, particularly those with obesity or type 2 diabetes.
Not a fit: Patients with liver disease due to alcohol consumption or other non-metabolic causes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively treat or even reverse nonalcoholic fatty liver disease.
How similar studies have performed: Previous research has shown promising results in targeting metabolic pathways in liver diseases, suggesting that this approach may be effective.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Norton, Luke — University of Texas Hlth Science Center
- Study coordinator: Norton, Luke
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.